Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.45 |
| ▸ | TTPA | P49638 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633931 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2140309 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6362676 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL22899966 | 0.90 | PTGS1 (0.70) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15851247 | 0.90 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL31326006 | 0.87 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30951067 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2393197 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL21344343 | 0.86 | PTGS1 (0.52) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL7895023 | 0.86 | PTGS1 (0.91) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126011-A | Method for chiral resolution of Trolox and Trolox ester compound enantiomer | 辽宁大学 | 2024-06-04 | — | — | CN | disclosed |
| US-20230330060-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SULFATEQ B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230202997-A1 | CHROMANOL, QUINONE OR HYDROQUINONE COMPOUNDS FOR TREATMENT OF SEPSIS | SULFATEQ B.V. (NL) | 2023-06-29 | — | — | US | disclosed |
| US-20230052152-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | SULFATEQ B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| CN-114746430-A | Quinone-, hydroquinone-and naphthoquinone-analogues of vattinoquinone for the treatment of mitochondrial disorders | 康德生物医疗有限公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202997-A1 | CHROMANOL, QUINONE OR HYDROQUINONE COMPOUNDS FOR TREATMENT OF SEPSIS | SQOR, SQLE, CYP11B2 | PTGS1 288/4885PTGS2 276/4885CYP1A2 43/4885 |
| US-20230330060-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SQOR, SDHA, NDUFV2 | PTGS1 550/4885PTGS2 454/4885CYP1A2 226/4885 |
| US-20230052152-A1 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | PSEN2, APP, SNCA | PTGS1 1348/4885PTGS2 878/4885CYP1A2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.